A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?

This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.

Detalles Bibliográficos
Autores principales: Shafiee, Arman, Teymouri Athar, Mohammad Mobin, Mozhgani, Sayed-Hamidreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005062/
https://www.ncbi.nlm.nih.gov/pubmed/36915278
http://dx.doi.org/10.2217/fvl-2023-0006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005062/
https://www.ncbi.nlm.nih.gov/pubmed/36915278
http://dx.doi.org/10.2217/fvl-2023-0006

Ejemplares similares